[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global COVID-19 Diagnostic Testing Market: Focus on Product Type, Sample Type, Technology, End User, Country Data (30 Countries), and Competitive Landscape - Analysis and Forecast, 3Q-2020-4Q-2021

October 2020 | 369 pages | ID: GC0739705D88EN
BIS Research Inc.

US$ 5,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Market Report Coverage - COVID-19 Diagnostic Testing

Market Segmentation
  • Product – Kits and Assays, and Instruments
  • Sample Type – Swabs, Blood Samples, Urine Samples, and Other Samples
  • Technology – Molecular Assays and Immunoassays
  • End User – Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Other End Users
Regional Segmentation
  • North America – U.S., Canada, and Rest-of-North America
  • Europe – Germany, U.K., France, Italy, Spain, Russia, Netherlands and Rest-of-Europe
  • Asia-Pacific – China, India, Japan, Taiwan, South Korea, Singapore, Australia, Bangladesh, Pakistan, Indonesia, and Rest-of-Asia-Pacific
  • Latin America – Brazil, Mexico, Peru, Argentina, Chile, and Rest-of-Latin America
  • Middle East – Kingdom of Saudi Arabia (KSA), Iran, United Arab Emirates (UAE), and Rest-of-Middle East
  • Africa – South Africa, Zimbabwe, Algeria, and Rest-of-Africa
  • Oceania/Rest-of-the-World
Growth Drivers
  • Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
  • Technological Innovation Resulting in Market Pull
  • Significant External Funding Supporting Market Growth
  • Favourable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products
Market Challenges
  • Less Efficiency of Rapid COVID-19 Diagnostic Testing as Compared with that of Laboratory Testing
  • Shortage of Skilled Professionals and Trained Lab-Technicians
  • Shortage of COVID-19 Diagnostic Test Reagents
  • Significant Dampening of the Market due to the Expected Launch of COVID-19 Vaccine
Market Opportunities
  • Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations
Key Companies Profiled

Abbott Laboratories, BGI Group, Becton, Dickinson and Company, bioM?rieux SA, Bio-Rad Laboratories, Inc., CENTOGENE Holding AG, Cellex Inc., CTK Biotech, Danaher Corporation, DiaSorin S.p.A, F. Hoffmann-La Roche Ltd, Hologic Inc., GenMark Diagnostics, PerkinElmer Inc., QIAGEN N.V., Luminex Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:
  • What are the major market drivers, challenges, and opportunities in the global COVID-19 diagnostic testing market?
  • What are the underlying structures resulting in the emerging trends within the global COVID-19 diagnostic testing market?
  • How the COVID-19 pandemic impacted the global healthcare system?
  • What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for COVID-19 diagnostic testing?
  • What is the reimbursement scenario for the global COVID-19 diagnostic testing market?
  • How each segment of the market is expected to grow during the forecast period from 3Q2020 to 4Q2021 and what is the anticipated revenue to be generated by each of the segments on the basis of:
    • Product Type (Kits and Assays, and Instruments)
    • Sample Type (Swabs, Blood Samples, Urine Samples, and Others)
    • Technology (Molecular Assays, and Immunoassays)
    • End User (Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Others)
    • Region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa, and Oceania/Rest-of-the-World
  • Who are the leading players with significant offerings to the global COVID-19 diagnostic testing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the major strategies adopted by the countries for COVID-19 diagnostic testing?
  • What are the current unmet needs that are being faced?
Market Overview

Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021. The market is driven by certain factors, which include rising cases of COVID-19 globally, inciting the development of diagnostic tests, technological innovation resulting in market pull, significant external funding supporting market growth, and favourable regulatory scenario aiding companies to launch COVID-19 diagnostic testing products.

The market is favoured by the developments in the field of COVID-19 diagnostic testing solutions, particularly kits and assays, which are being developed by the emerging and the legacy diagnostic companies worldwide. Currently, the COVID-19 diagnostic testing industry is witnessing upsurge on account of growing number of cases worldwide coupled with the massive issuance of emergency use authorizations (EUAs) from the regulatory bodies to the manufacturers.

Furthermore, several diagnostic companies are focusing on the development of point-of-care (POC) rapid COVID-19 diagnostics tests having higher sensitivity and low turn-around time to benefit the patients, further providing provisions for the healthcare professions to offer treatment modalities.

Within the research report, the market is segmented on the basis of product type, sample type, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of COVID-19 cases on the global level has created a buzz among the diagnostic companies to invest in the development of efficient and rapid diagnostic testing solutions. Due to the diverse product and pipeline portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as Danaher Corporation, PerkinElmer Inc., and F. Hoffmann-La Roche Ltd, have also launched their respective COVID-19 diagnostic testing products, such as Xpert Xpress SARS-CoV-2, PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay, and Cobas SARS-CoV-2 Test respectively, to compete with Abbott’s market dominance.

On the basis of region, Asia-Pacific (APAC) holds the largest share of the COVID-19 diagnostic testing market and is anticipated to grow at the fastest CQGR during the forecast period, 3Q2020-4Q2021. Growing number of COVID-19 cases, growing emphasis in the development of novel diagnostic technologies, and rising healthcare awareness, among others, are some of the factors attributable to its largest share in the market.
EXECUTIVE SUMMARY

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 COVID-19 Diagnostic Testing: Research Methodology
3.2 Data Sources
  3.2.1 Primary Data Sources
  3.2.2 Secondary Data Sources
3.3 Market Estimation Model

4 MARKET OVERVIEW

4.1 Market Definition
4.2 Impact of COVID-19 on Human Health
4.3 Implications of COVID-19 on the Healthcare Sector
4.4 Market Footprint and Growth Potential, Value ($Million), 2020-2021

5 INDUSTRY INSIGHTS

5.1 Overview
5.2 Legal Requirements and Framework in the U.S.
  5.2.1 Emergency Use Authorization (EUA)
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirement and Framework in the Asia-Pacific Region
  5.4.1 China
  5.4.2 Japan

6 MARKET DYNAMICS

6.1 Overview
6.2 Impact Analysis
6.3 Drivers
  6.3.1 Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
  6.3.2 Technological Innovation Resulting in Market Pull
  6.3.3 Significant External Funding Supporting Market Growth
  6.3.4 Favorable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products
6.4 Restraints
  6.4.1 Less Efficient Rapid COVID-19 Diagnostic Testing as Compared to Laboratory Testing
  6.4.2 Shortage of Skilled Professionals and Trained Lab-Technicians
  6.4.3 Shortage of COVID-19 Diagnostic Test Reagents
  6.4.4 Significant Dampening of the Market Due to the Expected Launch of COVID-19 Vaccine
  6.4.5 Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations

7 COMPETITIVE LANDSCAPE

7.1 Key Strategies and Developments
  7.1.1 Product Approvals
  7.1.2 Synergistic Activities
  7.1.3 Product Launch and Upgradations
  7.1.4 Business Expansion and Funding
7.2 Market Share Analysis

8 GLOBAL COVID-19 DIAGNOSTIC TESTING MARKET (BY PRODUCT)

8.1 Overview
8.2 Kits and Assays
8.3 Instruments

9 GLOBAL COVID-19 DIAGNOSTIC TESTING MARKET (BY SAMPLE TYPE)

9.1 Overview
9.2 Swabs
  9.2.1 Nasopharyngeal Swabs
  9.2.2 Oropharyngeal Swabs
9.3 Blood Samples
9.4 Urine Samples
9.5 Other Samples

10 GLOBAL COVID-19 DIAGNOSTIC TESTING MARKET (BY TECHNOLOGY)

10.1 Overview
10.2 Molecular Assays
  10.2.1 Polymerase Chain Reaction (PCR)
    10.2.1.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
    10.2.1.2 Droplet Digital Polymerase Chain Reaction (ddPCR)
  10.2.2 Isothermal Amplification
  10.2.3 Others
10.3 Immunoassays
  10.3.1 Lateral Flow Immunoassay (LFIA)
  10.3.2 Enzyme Immunoassay (EIA)

11 GLOBAL COVID-19 DIAGNOSTIC TESTING MARKET (BY END USER)

11.1 Overview
11.2 Hospitals and Healthcare Centers
11.3 Diagnostic Centers and Clinics
11.4 Research Institutions
11.5 Other End Users

12 GLOBAL COVID-19 DIAGNOSTIC TESTING MARKET (BY REGION)

12.1 Overview
12.2 North America
  12.2.1 U.S.
    12.2.1.1 Strategies Adopted by the U.S. for COVID-19 Diagnostic Testing
    12.2.1.2 U.S. COVID-19 Diagnostic Testing Market (by Technology)
      12.2.1.2.1 Molecular Assays
      12.2.1.2.2 Immunoassay
  12.2.2 Canada
    12.2.2.1 Strategies Adopted by Canada for COVID-19 Diagnostic Testing
    12.2.2.2 Canada COVID-19 Diagnostic Testing Market (by Technology)
      12.2.2.2.1 Molecular Assays
      12.2.2.2.2 Immunoassays
  12.2.3 Rest-of-North America
    12.2.3.1 Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology)
      12.2.3.1.1 Molecular Assays
      12.2.3.1.2 Immunoassays
12.3 Europe
  12.3.1 Germany
    12.3.1.1 Strategies Adopted by Germany for COVID-19 Diagnostic Testing
    12.3.1.2 Germany COVID-19 Diagnostic Testing Market (by Technology)
      12.3.1.2.1 Molecular Assays
      12.3.1.2.2 Immunoassays
  12.3.2 U.K.
    12.3.2.1 Strategies Adopted by the U.K. for COVID-19 Diagnostic Testing
    12.3.2.2 U.K. COVID-19 Diagnostic Testing Market (by Technology)
      12.3.2.2.1 Molecular Assays
      12.3.2.2.2 Immunoassays
  12.3.3 France
    12.3.3.1 Strategies Adopted by France for COVID-19 Diagnostic Testing
    12.3.3.2 France COVID-19 Diagnostic Testing Market (by Technology)
      12.3.3.2.1 Molecular Assays
      12.3.3.2.2 Immunoassays
  12.3.4 Italy
    12.3.4.1 Strategies Adopted by Italy for COVID-19 Diagnostic Testing
    12.3.4.2 Italy COVID-19 Diagnostic Testing Market (by Technology)
      12.3.4.2.1 Molecular Assays
      12.3.4.2.2 Immunoassays
  12.3.5 Spain
    12.3.5.1 Strategies Adopted by Spain for COVID-19 Diagnostic Testing
    12.3.5.2 Spain COVID-19 Diagnostic Testing Market (by Technology)
      12.3.5.2.1 Molecular Assays
      12.3.5.2.2 Immunoassays
  12.3.6 Russia
    12.3.6.1 Russia COVID-19 Diagnostic Testing Market (by Technology)
      12.3.6.1.1 Molecular Assays
      12.3.6.1.2 Immunoassays
  12.3.7 Netherlands
    12.3.7.1 Strategies Adopted by Netherlands for COVID-19 Diagnostic Testing
    12.3.7.2 Netherlands COVID-19 Diagnostic Testing Market (by Technology)
      12.3.7.2.1 Molecular Assays
      12.3.7.2.2 Immunoassays
  12.3.8 Rest-of-Europe
    12.3.8.1 Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology)
      12.3.8.1.1 Molecular Assays
      12.3.8.1.2 Immunoassays
12.4 Asia-Pacific
  12.4.1 China
    12.4.1.1 Strategies Adopted by China for COVID-19 Diagnostic Testing
    12.4.1.2 China COVID-19 Diagnostic Testing Market (by Technology)
      12.4.1.2.1 Molecular Assays
      12.4.1.2.2 Immunoassays
  12.4.2 India
    12.4.2.1 Strategies Adopted by India for COVID-19 Diagnostic Testing
    12.4.2.2 India COVID-19 Diagnostic Testing Market (by Technology)
      12.4.2.2.1 Molecular Assays
      12.4.2.2.2 Immunoassays
  12.4.3 Japan
    12.4.3.1 Strategies Adopted by Japan for COVID-19 Diagnostic Testing
    12.4.3.2 Japan COVID-19 Diagnostic Testing Market (by Technology)
      12.4.3.2.1 Molecular Assays
      12.4.3.2.2 Immunoassays
  12.4.4 Taiwan
    12.4.4.1 Strategies Adopted by Taiwan for COVID-19 Diagnostic Testing
    12.4.4.2 Taiwan COVID-19 Diagnostic Testing Market (by Technology)
      12.4.4.2.1 Molecular Assays
      12.4.4.2.2 Immunoassays
  12.4.5 South Korea
    12.4.5.1 Strategies Adopted by South Korea for COVID-19 Diagnostic Testing
    12.4.5.2 South Korea COVID-19 Diagnostic Testing Market (by Technology)
      12.4.5.2.1 Molecular Assays
      12.4.5.2.2 Immunoassays
  12.4.6 Singapore
    12.4.6.1 Strategies Adopted by Singapore for COVID-19 Diagnostic Testing
    12.4.6.2 Singapore COVID-19 Diagnostic Testing Market (by Technology)
      12.4.6.2.1 Molecular Assays
      12.4.6.2.2 Immunoassays
  12.4.7 Australia
    12.4.7.1 Strategies Adopted by Australia for COVID-19 Diagnostic Testing
    12.4.7.2 Australia COVID-19 Diagnostic Testing Market (by Technology)
      12.4.7.2.1 Molecular Assays
      12.4.7.2.2 Immunoassays
  12.4.8 Bangladesh
    12.4.8.1 Strategies Adopted by Bangladesh for COVID-19 Diagnostic Testing
    12.4.8.2 Bangladesh COVID-19 Diagnostic Testing Market (by Technology)
      12.4.8.2.1 Molecular Assays
      12.4.8.2.2 Immunoassays
  12.4.9 Pakistan
    12.4.9.1 Strategies Adopted by Pakistan for COVID-19 Diagnostic Testing
    12.4.9.2 Pakistan COVID-19 Diagnostic Testing Market (by Technology)
      12.4.9.2.1 Molecular Assays
      12.4.9.2.2 Immunoassays
  12.4.10 Indonesia
    12.4.10.1 Strategies Adopted by Indonesia for COVID-19 Diagnostic Testing
    12.4.10.2 Indonesia COVID-19 Diagnostic Testing Market (by Technology)
      12.4.10.2.1 Molecular Assays
      12.4.10.2.2 Immunoassays
  12.4.11 Rest-of-APAC(RoAPAC)
    12.4.11.1 Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology)
      12.4.11.1.1 Molecular Assays
      12.4.11.1.2 Immunoassays
12.5 Latin America
  12.5.1 Brazil
    12.5.1.1 Strategies Adopted by Brazil for COVID-19 Diagnostic Testing
    12.5.1.2 Brazil COVID-19 Diagnostic Testing Market (by Technology)
      12.5.1.2.1 Molecular Assays
      12.5.1.2.2 Immunoassays
  12.5.2 Mexico
    12.5.2.1 Strategies Adopted by Mexico for COVID-19 Diagnostic Testing
    12.5.2.2 Mexico COVID-19 Diagnostic Testing Market (by Technology)
      12.5.2.2.1 Molecular Assays
      12.5.2.2.2 Immunoassays
  12.5.3 Peru
    12.5.3.1 Strategies Adopted by Peru for COVID-19 Diagnostic Testing
    12.5.3.2 Peru COVID-19 Diagnostic Testing Market (by Technology)
      12.5.3.2.1 Molecular Assays
      12.5.3.2.2 Immunoassays
  12.5.4 Argentina
    12.5.4.1 Strategies Adopted by Argentina for COVID-19 Diagnostic Testing
    12.5.4.2 Argentina COVID-19 Diagnostic Testing Market (by Technology)
      12.5.4.2.1 Molecular Assays
      12.5.4.2.2 Immunoassays
  12.5.5 Chile
    12.5.5.1 Strategies Adopted by Chile for COVID-19 Diagnostic Testing
    12.5.5.2 Chile COVID-19 Diagnostic Testing Market (by Technology)
      12.5.5.2.1 Molecular Assays
      12.5.5.2.2 Immunoassays
  12.5.6 Rest-of-Latin America (RoLA)
    12.5.6.1 Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology)
      12.5.6.1.1 Molecular Assays
      12.5.6.1.2 Immunoassays
12.6 Middle East
  12.6.1 Kingdom of Saudi Arabia
    12.6.1.1 Strategies Adopted by KSA for COVID-19 Diagnostic Testing
    12.6.1.2 KSA COVID-19 Diagnostic Testing Market (by Technology)
      12.6.1.2.1 Molecular Assays
      12.6.1.2.2 Immunoassays
  12.6.2 Iran
    12.6.2.1 Strategies Adopted by Iran for COVID-19 Diagnostic Testing
    12.6.2.2 Iran COVID-19 Diagnostic Testing Market (by Technology)
      12.6.2.2.1 Molecular Assays
      12.6.2.2.2 Immunoassays
  12.6.3 United Arab Emirates (U.A.E.)
    12.6.3.1 U.A.E. COVID-19 Diagnostic Testing Market (by Technology)
      12.6.3.1.1 Molecular Assays
      12.6.3.1.2 Immunoassays
  12.6.4 Rest-of-Middle East
    12.6.4.1 Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology)
      12.6.4.1.1 Molecular Assays
      12.6.4.1.2 Immunoassays
12.7 Africa
  12.7.1 South Africa
    12.7.1.1 Strategies Adopted by South Africa for COVID-19 Diagnostic Testing
    12.7.1.2 South Africa COVID-19 Diagnostic Testing Market (by Technology)
      12.7.1.2.1 Molecular Assays
      12.7.1.2.2 Immunoassays
  12.7.2 Zimbabwe
    12.7.2.1 Zimbabwe COVID-19 Diagnostic Testing Market (by Technology)
      12.7.2.1.1 Molecular Assays
      12.7.2.1.2 Immunoassays
  12.7.3 Algeria
    12.7.3.1 Algeria COVID-19 Diagnostic Testing Market (by Technology)
      12.7.3.1.1 Molecular Assays
      12.7.3.1.2 Immunoassays
  12.7.4 Rest-of-Africa
    12.7.4.1 Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology)
      12.7.4.1.1 Molecular Assays
      12.7.4.1.2 Immunoassays
12.8 Oceania/Rest-of-the-World
  12.8.1 Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology)
  12.8.2 Molecular Assays
  12.8.3 Immunoassays

13 COMPANY PROFILES

13.1 Overview
13.2 Abbott Laboratories
  13.2.1 Company Overview
  13.2.2 BIS Insights
13.3 BGI Group
  13.3.1 Company Overview
  13.3.2 BIS Insights
13.4 Becton, Dickinson and Company
  13.4.1 Company Overview
  13.4.2 BIS Insights
13.5 BioMerieux SA
  13.5.1 Company Overview
  13.5.2 BIS Insights
13.6 Bio-Rad Laboratories, Inc.
  13.6.1 Company Overview
  13.6.2 BIS Insights
13.7 CENTOGENE Holding AG
  13.7.1 Company Overview
  13.7.2 BIS Insights
13.8 Cellex Inc.
  13.8.1 Company Overview
  13.8.2 BIS Insights
13.9 CTK Biotech
  13.9.1 Company Overview
  13.9.2 BIS Insights
13.1 Danaher Corporation
  13.10.1 Company Overview
  13.10.2 BIS Insights
13.11 DiaSorin S.p.A
  13.11.1 Company Overview
  13.11.2 BIS Insights
13.12 F. Hoffmann-La Roche Ltd
  13.12.1 Company Overview
  13.12.2 BIS Insights
13.13 Hologic, Inc.
  13.13.1 Company Overview
  13.13.2 BIS Insights
13.14 GenMark Diagnostics
  13.14.1 Company Overview
  13.14.2 BIS Insights
13.15 PerkinElmer Inc.
  13.15.1 Company Overview
  13.15.2 BIS Insights
13.16 QIAGEN N.V.
  13.16.1 Company Overview
  13.16.2 BIS Insights
13.17 Quidel Corporation
  13.17.1 Company Overview
  13.17.2 BIS Insights
13.18 Luminex Corporation
  13.18.1 Company Overview
  13.18.2 BIS Insights
13.19 Siemens Healthineers AG
  13.19.1 Company Overview
  13.19.2 BIS Insights
13.2 Thermo Fisher Scientific Inc.
  13.20.1 Company Overview
  13.20.2 BIS Insights

LIST OF FIGURES

Figure 1: Global COVID-19 Cumulative Cases
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global COVID-19 Diagnostic Testing Market
Figure 3: Global COVID-19 Diagnostic Testing Market (by Product), Value ($Million), 2Q2020-4Q2021
Figure 4: Global COVID-19 Diagnostic Testing Market (by Sample Type), Value ($Million), 2Q2020-4Q2021
Figure 5: Global COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 2Q2020-4Q2021
Figure 6: Global COVID-19 Diagnostic Testing Market (by End User), Value ($Million), 2Q2020-4Q2021
Figure 7: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 2Q2020-4Q2021
Figure 2.1: Global COVID-19 Diagnostic Testing Market Segmentation
Figure 3.1: Global COVID-19 Diagnostic Testing Market: Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Implications of COVID-19 on the Healthcare Sector: Short- and Long-Term Analysis
Figure 4.2: Global COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020 and 4Q2021
Figure 5.1: Procedure for Obtaining Emergency Use Authorization (EUA)
Figure 5.2: Components Considered for Clinical Evidence as per the IVDR
Figure 5.3: Procedure for IVD Medical Device Registration in China
Figure 6.1: Number of COVID-19 Confirmed Cases, Globally
Figure 7.1: Share of Key Developments and Strategies, January 2020 - July 2020
Figure 7.2: Product Approval Share (by Company), January 2020 – July 2020
Figure 7.3: Synergistic Activities Share (by Company), January 2020 – July 2020
Figure 7.4: Product Launch and Upgradations Share (by Company), January 2020 – July 2020
Figure 7.6: Market Share Analysis for Global COVID-19 Diagnostic Testing Market, 2Q2020
Figure 8.1: Global COVID-19 Diagnostic Testing Market (by Product Type)
Figure 8.2: Global COVID-19 Diagnostic Testing Market (by Product Type), 2Q2020 and 4Q2021
Figure 8.3: Global COVID-19 Diagnostic Testing Market (for Kits and Assays), Value ($Million), 1Q2020-4Q2021
Figure 8.4: Global COVID-19 Diagnostic Testing Market (for Instruments), Value ($Million), 1Q2020-4Q2021
Figure 9.1: Global COVID-19 Diagnostic Testing Market (by Sample Type)
Figure 9.2: Global COVID-19 Diagnostic Testing Market (by Sample Type), 2Q2020-4Q2021
Figure 9.3: Global COVID-19 Diagnostic Testing Market (by Swab), 2Q2020 and 4Q2021
Figure 9.4: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
Figure 9.5: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
Figure 9.6: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
Figure 9.7: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
Figure 9.8: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Volume (Thousand Units), 1Q2020-4Q2021
Figure 9.9: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Value ($Million), 1Q2020-4Q2021
Figure 9.10: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Volume (Thousand Units), 1Q2020-4Q2021
Figure 9.11: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Value ($Million), 1Q2020-4Q2021
Figure 9.12: Global COVID-19 Diagnostic Testing Market (for Other Samples), Volume (Thousand Units), 1Q2020-4Q2021
Figure 9.13: Global COVID-19 Diagnostic Testing Market (for Other Samples), Value ($Million), 1Q2020-4Q2021
Figure 10.1: Global COVID-19 Diagnostic Testing Market (by Technology)
Figure 10.2: Global COVID-19 Diagnostic Testing Market (by Technology), 2Q2020-4Q2021
Figure 10.3: Global COVID-19 Diagnostic Testing Market (by Molecular Assays), 2Q2020 and 4Q2021
Figure 10.4: Global COVID-19 Diagnostic Testing Market (for PCR), Value ($Million), 1Q2020-4Q2021
Figure 10.5: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.6: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Value ($Million), 1Q2020-4Q2021
Figure 10.7: Global COVID-19 Diagnostic Testing Market (for ddPCR), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.8: Global COVID-19 Diagnostic Testing Market (for ddPCR), Value ($Million), 1Q2020-4Q2021
Figure 10.9: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.10: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Value ($Million), 1Q2020-4Q2021
Figure 10.11: Global COVID-19 Diagnostic Testing Market (for Others), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.12: Global COVID-19 Diagnostic Testing Market (for Others), Value ($Million), 1Q2020-4Q2021
Figure 10.13: Global COVID-19 Diagnostic Testing Market (by Immunoassays), 2Q2020 and 4Q2021
Figure 10.14: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.15: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Value ($Million), 1Q2020-4Q2021
Figure 10.16: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
Figure 10.17: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Value ($Million), 1Q2020-4Q2021
Figure 11.1: Global COVID-19 Diagnostic Testing Market (by End User)
Figure 11.2: Global COVID-19 Diagnostic Testing Market (by End User), 2Q2020-4Q2021
Figure 11.3: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Volume (Thousand Units), 1Q2020-4Q2021
Figure 11.4: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Value ($Million), 1Q2020-4Q2021
Figure 11.5: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Volume (Thousand Units), 1Q2020-4Q2021
Figure 11.6: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Value ($Million), 1Q 2020-4Q2021
Figure 11.7: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Volume (Thousand Units), 1Q2020-4Q2021
Figure 11.8: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Value ($Million), 1Q2020-4Q2021
Figure 11.9: Global COVID-19 Diagnostic Testing Market (for Other End Users), Volume (Thousand Units), 1Q2020-4Q2021
Figure 11.10: Global COVID-19 Diagnostic Testing Market (for Other End Users), Value ($Million), 1Q2020-4Q2021
Figure 12.1: Global COVID-19 Diagnostic Testing Market (by Region)
Figure 12.2: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 1Q2020-4Q2021
Figure 12.3: Global COVID-19 Diagnostic Testing Market (by Region), 1Q2020 and 4Q2021
Figure 12.4: North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.5: North America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.6: North America: Market Dynamics
Figure 12.7: U.S. COVID-19 Diagnostic Testing Market, Value (Million), 1Q2020-4Q2021
Figure 12.8: U.S. Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.9: U.S. COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
Figure 12.10: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.11: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
Figure 12.12: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.13: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Value ($Million), 2020-2021
Figure 12.14: Canada COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.15: Canada Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.16: Canada COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
Figure 12.17: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), Q12020-4Q2021
Figure 12.18: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.19: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), Q12020-Q42021
Figure 12.20: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.21: Rest-of-North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.22: Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.23: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.24: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
Figure 12.25: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.26: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.27: Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.28: Europe: Market Dynamics
Figure 12.29: Europe COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.30: Germany COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.31: Germany Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.32: Germany COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.33: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.34: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.35: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.36: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.37: U.K. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.38: U.K. Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.39: U.K. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.40: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.41: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.42: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.43: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.44: France COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.45: France Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.46: France COVID-19 Diagnostic Testing Market (by Technology), Value ($Million) 1Q2020-4Q2021
Figure 12.47: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.48: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.49: France COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.50: France COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.51: Italy COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.52: Italy Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.53: Italy COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.54: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.55: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.56: Italy COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.57: Italy COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.58: Spain COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.59: Spain Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.60: Spain COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.61: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.62: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.63: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.64: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.65: Russia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.66: Russia Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.67: Russia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.68: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.69: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.70: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.71: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.72: Netherlands COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.73: Netherlands Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.74: Netherlands COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.75: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.76: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.77: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.78: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.79: Rest-of-Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.80: Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.81: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.82: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
Figure 12.83: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.84: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.85: Asia-Pacific COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.86: APAC: Market Dynamics
Figure 12.87: APAC COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.88: China COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.89: China Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.90: China COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.91: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.92: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.93: China COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.94: China COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.95: India COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.96: India Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.97: India COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.98: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.99: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.100: India COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.101: India COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.102: Japan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.103: Japan Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.104: Japan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.105: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.106: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.107: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.108: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.109: Taiwan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.110: Taiwan Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.111: Taiwan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.112: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.113: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.114: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.115: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.116: South Korea COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.117: South Korea Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.118: South Korea COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.119: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.120: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.121: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.122: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.123: Singapore COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.124: Singapore Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.125: Singapore COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.126: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.127: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.128: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.129: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.130: Australia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.131: Australia Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.132: Australia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.133: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.134: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.135: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.136: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.137: Bangladesh COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.138: Bangladesh Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.139: Bangladesh COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.140: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.141: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.142: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.143: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.144: Pakistan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.145: Pakistan Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.146: Pakistan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.147: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.148: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.149: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.150: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.151: Indonesia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.152: Indonesia Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.153: Indonesia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.154: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume, 1Q2020-4Q2021
Figure 12.155: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.156: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.157: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.158: RoAPAC COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.159: Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.160: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.161: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
Figure 12.162: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.163: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.164: Latin America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.165: Latin America: Market Dynamics
Figure 12.166: Latin America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.167: Brazil COVID-19 Diagnostic Testing Market, Value ($Million), 3Q2020-4Q2021
Figure 12.168: Brazil Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.169: Brazil COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.170: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.171: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.172: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.173: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.174: Mexico COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.175: Mexico Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.176: Mexico COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.177: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.178: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.179: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.180: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.181: Peru COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.182: Peru Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.183: Peru COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.184: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.185: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.186: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.187: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.188: Argentina COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.189: Argentina Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.190: Argentina COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.191: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.192: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.193: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.194: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.195: Chile COVID-19 Diagnostic Testing Market, $Million, Q12020-Q42021
Figure 12.196: Chile Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.197: Chile COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.198: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.199: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.200: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.201: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.202: RoLA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.203: Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.204: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.205: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
Figure 12.206: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.207: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.208: Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.209: Middle East: Market Dynamics
Figure 12.210: Middle East COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.211: KSA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.212: KSA Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.213: KSA COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.214: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.215: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.216: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.217: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.218: Iran COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.219: Iran Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.220: Iran COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.221: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.222: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.223: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.224: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.225: U.A.E. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.226: U.A.E. Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.227: U.A.E. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.228: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.229: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.230: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.231: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.232: Rest-of-Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.233: Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.234: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.235: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.236: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.237: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.238: Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.239: Africa: Market Dynamics
Figure 12.240: Africa COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
Figure 12.241: South Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.242: South Africa Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.243: South Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.244: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.245: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.246: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.247: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.248: Zimbabwe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.249: Zimbabwe Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.250: Zimbabwe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.251: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.252: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.253: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.254: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.255: Algeria COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.256: Algeria Month-Wise COVID-19 Cases, as of August 15, 2020
Figure 12.257: Algeria COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.258: Algeria COVID-19 Diagnostic Testing Market (by Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.259: Algeria COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.260: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.261: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.262: Rest-of-Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.263: Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.264: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.265: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.266: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.267: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 12.268: Oceania/RoW COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
Figure 12.269: Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
Figure 12.270: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.271: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
Figure 12.272: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
Figure 12.273: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Competitive Benchmarking of Abbott Laboratories
Figure 13.3: Competitive Benchmarking of BGI Group
Figure 13.4: Competitive Benchmarking of Becton, Dickinson and Company
Figure 13.5: Competitive Benchmarking of BioMerieux SA
Figure 13.6: Competitive Benchmarking of Bio-Rad Laboratories, Inc.
Figure 13.7: Competitive Benchmarking of CENTOGENE Holding AG
Figure 13.8: Competitive Benchmarking of Cellex Inc.
Figure 13.9: Competitive Benchmarking of CTK Biotech
Figure 13.10: Competitive Benchmarking of Danaher Corporation
Figure 13.11: Competitive Benchmarking of DiaSorin S.p.A
Figure 13.12: Competitive Benchmarking of F. Hoffmann-La Roche Ltd
Figure 13.13: Competitive Benchmarking of Hologic, Inc.
Figure 13.14: Competitive Benchmarking of GenMark Diagnostics
Figure 13.15: Competitive Benchmarking of PerkinElmer Inc.
Figure 13.16: Competitive Benchmarking of QIAGEN N.V.
Figure 13.17: Competitive Benchmarking of Quidel Corporation
Figure 13.18: Competitive Benchmarking of Luminex Corporation
Figure 13.19: Competitive Benchmarking of Siemens Healthineers AG
Figure 13.20: Competitive Benchmarking of Thermo Fisher Scientific Inc.

LIST OF TABLES

Table 5.1: Registration Criteria for IVD Medical Devices as per the NMPA
Table 6.1: Impact Analysis of Market Drivers
Table 6.2: Impact Analysis of Market Restraints
Table 12.1: Key Players Offering Molecular Assays in the U.S.
Table 12.2: Key Players Offering Immunoassays in the U.S.
Table 12.3: Key Players Offering Molecular Assays in Canada
Table 12.4: Key Players Offering Immunoassays in Canada
Table 12.5: Key Players Offering Molecular Assays in Germany
Table 12.6: Key Players Offering Immunoassays in Germany
Table 12.7: Key Players Offering Molecular Assays in the U.K.
Table 12.8: Key Players Offering Immunoassays in the U.K.
Table 12.9: Key Players Offering Molecular Assays in France
Table 12.10: Key Players Offering Molecular Assays in France
Table 12.11: Key Players Offering Molecular Assays in Italy
Table 12.12: Key Players Offering Immunoassays in Italy
Table 12.13: Key Players Offering Molecular Assays in Spain
Table 12.14: Key Players Offering Immunoassays in Spain
Table 12.15: Key Players Offering Molecular Assays in Netherlands
Table 12.17: Key Players Offering Molecular Assays in China
Table 12.18: Key Players Offering Immunoassays in China
Table 12.19: Key Players Offering Molecular Assays in India
Table 12.20: Key Players Offering Immunoassays in India
Table 12.21: Key Players Offering Molecular Assays in Japan
Table 12.22: Key Players Offering Immunoassays in Japan
Table 12.23: Key Players Offering Molecular Assays in Taiwan
Table 12.24: Key Players Offering Molecular Assays in South Korea
Table 12.25: Key Players Offering Immunoassays in South Korea
Table 12.26: Key Players Offering Molecular Assays in Singapore
Table 12.27: Key Players Offering Immunoassays in Singapore
Table 12.28: Key Players Offering Molecular Assays in Australia
Table 12.29: Key Players Offering Immunoassays in Australia


More Publications